Strong YoY growth masks sequential flatness; Gagillapur clearance is near-term pivotal

Delivered ₹1476.8 Cr, +22% YoY confirmed. Call cites ₹1,477 Cr (rounding).

Delivered ₹180.0 Cr, +59.8% YoY (call rounds to 60%). Q4 PAT must have been ~₹112.6 Cr; Q1 shows -10.7% QoQ decline.

No conflict in delivered result; YoY margin expansion evident from 22.9% EBITDA margin at higher growth.

Call claims mix shift driving 74 bps EBITDA margin expansion. Supported by strong YoY growth and EBITDA +256 bps.

Delivered ₹1476.8 Cr Q1 vs prior QoQ +0.4% only. Not emphasized on call; contradicts 'strongest ever' framing.

Confirmed YoY; but sequential softness held intentionally due to pricing/cost pressures. Candid admission undermines growth narrative.

CHF5M ≈ ₹40 Cr annualized. Call projects PAT positive on annual basis FY27; Q1 showed EBITDA loss ₹12 Cr due to project mix.

FY26 call: 'PAT positive on annual basis FY27'. Now: 'USD 50M revenue by mid-FY29 with 30% EBITDA, 3 customer wins.' Quantified and hardened the target.

FY26 call implied <50% mix; Q1 FY27 now 50% of finished dosages (from 39% YoY). Driving margin expansion +256 bps.

Still pending FDA clearance; no new approvals. 7 of 8 facilities have clean EIR but Gagillapur remains blocked. Waiting behind clearance: 9 applications ready.

FY27 capex ₹600 Cr on-track (₹89 Cr spent Q1). Genome Valley investment complete; next phase: digitalization, modular growth at existing facilities.

We are quite excited and positive that the growth will continue. Yes, we are confident it will continue.

RM pressures are quite high with many challenges. But mix toward complex generics helps. We have every reason to believe it will continue.

Planned growth in both API and FDF business. Strong demand from products filed in past Europe. Upward trajectory going forward.

Complex products are difficult to make. ADHD products require low dosages and consistency—manufacturing very difficult. Sodium oxybate sole first-to-file, very complex product; many tried and failed.

USD 50 million revenue with 30%+ EBITDA somewhere mid-third year from now (mid-FY29) should be run rate. 3 customer wins at $10M+ each proof of concept.

No sequential revenue growth means no additional working capital needed. Substantially reduced receivables with higher USA sales where receivable days are better.

5-year period is the question target. Validation of that number should come in middle of that journey (mid-FY29).

Objective is very single force: turn PAT positive for this year. Quarterly run-rate minimum if multiplied by 4 for annual.

Only intentional stop for couple days. Post that never stopped production till date. Demand always there, supply always there. Only new product approvals stopped.

Initial estimates roughly INR 100 Cr intermediate, INR 200 Cr API investment plan. Will not be realized in first year.

Not a big one-off. Project-to-product mix variation. Opex varies quarter-to-quarter. Long cycle-time projects monetize later in H2.

Currently utilization levels very low. By year-end expect to cross 50%.

Not really demand trend; mix of both. Cost pressures on legacy 5 business. Couldn't pass pricing so held some demand. Intentional hold of supply due to pricing and costing pressures.

Filed 2 ANDAs so far. 1 ANDA US, 2 dossiers Europe, ~14 extensions in various countries. 9-13 products in dev across oncology.

Currently 70% capacity utilization. Large leeway ahead. Small expansion needed by end of '28. GPI products are low volume, high-value; 70% not comparable to large-volume facility.

These are litigation-based products. I do not have freedom to talk about timelines.

Management stated confident continued growth given 22% Q1 YoY and strong YoY trajectory. However sequential stasis (+0.4% QoQ) undermines confidence.

Q1 delivered 22.9% already at high end. Mix help from complex generics expected to offset RM inflation, but pricing power limited (Europe hold evident).

Genome Valley completed. Remaining capex for digitalization, modular growth at existing, peptide intermediate (INR 100 Cr) and API (INR 200 Cr) spread over multiple years.

FDA inspection awaited. 9 applications queued for launch pending clearance. No approval yet despite 7 other facilities EIR-clean. Delay extends revenue unlock.

Management acknowledged RM inflation 'quite high' with challenges in supply chain costs (freight, packing). Europe business intentionally held supply due to inability to pass pricing. Margin guidance 22-23% at risk.

Revenue essentially flat QoQ (+0.4% only); PAT down -10.7% QoQ. Q1 dubbed 'strongest ever' based on YoY metrics, masking QoQ stasis. Sequential momentum loss suggests growth headwinds.

Q1 peptide EBITDA showed INR -12 Cr loss despite CHF 5 Mn revenue (~₹40 Cr run-rate annualized). Project mix, long cycle times cause quarterly lumpiness. PAT positive target FY27 assumes strong H2.

Genome Valley complex generics facility and Peptide GLS facility both at 'very low' utilization. Expected to cross 50% by year-end only. Capex-heavy FY27 (₹600 Cr guided) with returns deferred.

Multiple controlled substance products (Dyanavel, Adzenys, sodium oxybate) timing dependent on litigation/IP expiry. Management cannot disclose timelines. 9 of 18 pending USA approvals are IP-based.